Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation
ACS Nano · 30.04.2024 · 18 (17) · 11335-11348
DOI: 10.1021/acsnano.4c00768 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 15.04.2024. Verfasst von Jeonghwan Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Messenger, Aerosols, Liposomes. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Rare Air Health, Inc..
Abstract (Originalsprache)
Leveraging the extensive surface area of the lungs for gene therapy, the inhalation route offers distinct advantages for delivery. Clinical nebulizers that employ vibrating mesh technology are the standard choice for converting liquid medicines into aerosols. However, they have limitations when it comes to delivering mRNA through inhalation, including severe damage to nanoparticles due to shearing forces. Here, we introduce a microfluidic aerosolization platform (MAP) that preserves the structural and physicochemical integrity of lipid nanoparticles, enabling safe and efficient delivery of mRNA to the respiratory system. Our results demonstrated the superiority of the MAP over the conventional vibrating mesh nebulizer, as it avoided problems such as particle aggregation, loss of mRNA encapsulation, and deformation of the nanoparticle morphology. Notably, aerosolized nanoparticles generated by the microfluidic device led to enhanced transfection efficiency across various cell lines. In vivo experiments with mice that inhaled these aerosolized nanoparticles revealed successful lung-specific mRNA transfection without observable signs of toxicity. This MAP may represent an advancement for the pulmonary gene therapy, enabling precise and effective delivery of aerosolized nanoparticles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States.
- College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
- Funai Microfluidic Systems, Lexington, Kentucky 40508, United States.
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon 97201, United States.
- Department of Biomedical Engineering, Robertson Life Sciences Building, Oregon Health & Science University, Portland, Oregon 97201, United States.
- Center for Innovative Drug Delivery and Imaging, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States.
ORCID-Profile: Jeonghwan Kim, Gaurav Sahay
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Rare Air Health, Inc.
Zitieren
APA
Kim, J., Jozić, A., Bloom, E., Jones, B., Marra, M., Murthy, N. T. V., Eygeris, Y., & Sahay, G. (2024). Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation. ACS Nano, 18(17), 11335-11348. https://doi.org/10.1021/acsnano.4c00768
Vancouver
Kim J, Jozić A, Bloom E, Jones B, Marra M, Murthy NTV, et al. Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation. ACS Nano. 2024;18(17):11335-11348. doi:10.1021/acsnano.4c00768
BibTeX
@article{Kim2024,
author = {Kim, Jeonghwan and Jozić, Antony and Bloom, Elissa and Jones, Brian and Marra, Michael and Murthy, Namratha Turuvekere Vittala and Eygeris, Yulia and Sahay, Gaurav},
title = {Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {17},
pages = {11335--11348},
doi = {10.1021/acsnano.4c00768}
}
EUVIMED